Reuters logo
BRIEF-ZIOPHARM jumps in premarket after palifosfamide reached target number of progression-free survival events
February 12, 2013 / 2:10 PM / 5 years ago

BRIEF-ZIOPHARM jumps in premarket after palifosfamide reached target number of progression-free survival events

NEW YORK, Feb 12 (Reuters) - ZIOPHARM Oncology Inc : * Jumps 14.5 percent to $4.57 in premarket after palifosfamide reached target number of progression-free survival events

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below